Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: Final results of a multicentric study in the United States

Armin Rashidi, Meghan Riley, Teresa A. Goldin, Farzaneh Sayedian, Michael G. Bayerl, Nadine S. Aguilera, Jeffrey A. Vos, Ranjit K. Goudar, Stephen I. Fisher

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Early death (ED) occurs in 10-30% of patients with acute promyelocytic leukemia (APL). Is all- trans retinoic acid (ATRA) promptly given and does it decrease overall early mortality? ATRA was administered within 24. h of morphological suspicion in only 44% of the 120 consecutive patients treated in the four collaborating centers. Absence of disseminated intravascular coagulation (p= 0.012) and admission to a non-university-affiliated hospital (p= 0.032) were independent predictors of ATRA delay. ED occurred in 17% of patients, and was independently correlated only with ICU admission (p= 0.002). Our results do not demonstrate that prompt (versus delayed) ATRA administration decreases overall early death.

Original languageEnglish (US)
Pages (from-to)1036-1040
Number of pages5
JournalLeukemia Research
Volume38
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • ATRA
  • Death
  • Leukemia
  • Promyelocytic

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: Final results of a multicentric study in the United States'. Together they form a unique fingerprint.

  • Cite this